Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. (PubMed)

Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. To compare the efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC).Systematic review and network meta-analysis.PubMed, Embase, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and several

2019 BMJ

2. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. (PubMed)

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination

2019 Lancet

3. Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details

Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details | CADTH.ca Find the information you need Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Project Number pCODR 10183 Brand Name Lorbrena Generic Name Lorlatinib Tumour Type Lung Indication Non-Small Cell Lung Cancer (NSCLC) Funding Request For the treatment of adult patients with anaplastic (...) lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib. Review Status Under Review Pre Noc Submission No NOC Date Manufacturer Pfizer Canada ULC Sponsor Pfizer Canada ULC Submission Date June 11, 2019 Submission Deemed Complete June 25, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ June 25, 2019 Check-point meeting

2019 CADTH - Pan Canadian Oncology Drug Review

4. ALK Inhibitors for Non–Small Cell Lung Cancer

ALK Inhibitors for Non–Small Cell Lung Cancer ALK Inhibitors for Non–Small Cell Lung Cancer | CADTH.ca Find the information you need ALK Inhibitors for Non–Small Cell Lung Cancer ALK Inhibitors for Non–Small Cell Lung Cancer Last updated: February 20, 2019 Project Number: HE0017-000 Product Line: Technology Review Result type: Report Lung cancer is the second-most commonly diagnosed cancer in both men and women, and is the leading cause of cancer deaths in Canada. Rearrangement (...) of the Anaplastic Lymphoma Kinase (ALK) gene drives the development of about 5% of non–small cell lung cancers (NSCLC). Inhibitors of ALK can effectively delay progression of these malignancies and are the treatment of choice in the first-line and subsequent line settings. This drug class is expanding and new products are poised to enter the market. Reviews of the comparative clinical and cost-effectiveness of ALK inhibitors, and of guidelines pertaining to their use, were requested by Canadian decision-makers

2019 Publication 4890897

5. Metastatic Non-Small-Cell Lung Cancer

Metastatic Non-Small-Cell Lung Cancer Updated version published 18 September 2019 by the ESMO Guidelines Committee © European Society for Medical Oncology 2019. All rights reserved. 1 CLINICAL PRACTICE GUIDELINES Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † Originally published in 2018 – Ann Oncol (2018) 29 (suppl 4): iv192–iv237 D. Planchard 1 , S. Popat 2 , K. Kerr 3 , S. Novello 4 , E. F. Smit 5 , C. Faivre-Finn 6 , T. S (...) of Cancer Sciences, University of Manchester, Manchester, UK; 7 Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; 8 LungenClinic Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany; 9 Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp, Belgium; 10 Weill Cornell Medical College, New York, USA; 11 Medical Oncology, Centre Hospitalier Universitaire

2019 European Society for Medical Oncology

6. Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive

Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive Drug Approval Package: ROZLYTREK U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ROZLYTREK Company: Genentech Application Number: 212725, 212726 Approval Date: 08/15/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2019 FDA - Drug Approval Package

7. Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details

Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details | CADTH.ca Find the information you need Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Project Number pCODR 10158 Brand Name Mvasi Generic Name Bevacizumab Strength 100 mg and 400 mg Tumour (...) Type Gastrointestinal / Lung Indication Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar Funding Request For first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen Review Status Final Biosimilar Dossier Issued Pre

2019 CADTH - Pan Canadian Oncology Drug Review

8. Tagrisso for Non-Small Cell Lung Cancer (first line) – Details

Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Tagrisso for Non-Small Cell Lung Cancer (first line) – Details | CADTH.ca Find the information you need Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Project Number pCODR 10137 Brand Name Tagrisso Generic Name Osimertinib Strength 40 mg and 80 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer (first line) Funding Request For the first-line (...) treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date July 10, 2018 Manufacturer AstraZeneca Canada Inc. Sponsor AstraZeneca Canada Inc. Submission Date May 16, 2018 Submission Deemed Complete May 24, 2018 Submission Type New Indication Prioritization Requested Requested and Not Granted Stakeholder Input Deadline ‡ May

2019 CADTH - Pan Canadian Oncology Drug Review

9. Tecentriq for Small Cell Lung Cancer – Details

Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details Project Number pCODR 10156 Brand Name Tecentriq Generic Name Atezolizumab Strength 60 mg/mL Tumour Type Lung Indication Small Cell Lung Cancer (SCLC) Funding Request For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC

2019 CADTH - Pan Canadian Oncology Drug Review

10. Imfinzi for Non-Small Cell Lung Cancer – Details

Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details Project Number pCODR 10131 Brand Name Imfinzi Generic Name Durvalumab Strength 50 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC

2019 CADTH - Pan Canadian Oncology Drug Review

11. Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details

Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Project Number pCODR 10151 Brand Name Xalkori Generic Name Crizotinib Strength 200 mg & 250 mg Tumour Type Lung Indication ROS1-positive advanced Non-Small Cell Lung (...) Cancer Funding Request As a single agent as first-line treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) Review Status Notification to Implement Issued Pre Noc Submission No NOC Date August 28, 2017 Manufacturer Pfizer Canada Inc. Sponsor Cancer Care Ontario Lung Cancer Drug Advisory Committee Submission Date October 30, 2018 Submission Deemed Complete November 13, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ November 13

2019 CADTH - Pan Canadian Oncology Drug Review

12. Vizimpro for Non-Small Cell Lung Cancer – Details

Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details Project Number pCODR 10129 Brand Name Vizimpro Generic Name Dacomitinib Strength 15 mg, 30 mg & 45 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the first-line treatment of patients with locally advanced or metastatic non (...) ‑small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date February 26, 2019 Manufacturer Pfizer Canada Inc. Sponsor Pfizer Canada Inc. Submission Date September 19, 2018 Submission Deemed Complete October 3, 2018 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ October 3, 2018 Check-point meeting December 4, 2018 pERC Meeting March 21, 2019 Initial

2019 CADTH - Pan Canadian Oncology Drug Review

13. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. (PubMed)

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC.In this open-label, phase 3 trial, we randomly assigned

2019 NEJM

14. Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC)

Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC) 1 Published 9 September 2019 1 SMC2184 dacomitinib 15mg, 30mg and 45mg film-coated tablets (Vizimpro®) Pfizer Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life and orphan (...) medicine process dacomitinib (Vizimpro ® ) is accepted for use within NHSScotland. Indication under review: as monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. In an open-label, randomised, phase III study, dacomitinib significantly improved progression-free survival compared with another EGFR tyrosine kinase inhibitor in adults with locally advanced

2019 Scottish Medicines Consortium

15. Osimertinib (Tagrisso) - non-small cell lung cancer (NSCLC)

Osimertinib (Tagrisso) - non-small cell lung cancer (NSCLC) 1 Published 9 September 2019 1 SMC2171 osimertinib 40mg and 80mg film-coated tablet (Tagrisso®) AstraZeneca Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the end of life and orphan (...) equivalent process osimertinib (Tagrisso ® ) is not recommended for use within NHSScotland. Indication under review: as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. Osimertinib, compared with two other EGFR tyrosine kinase inhibitors, improved progression-free survival in adults with locally advanced or metastatic NSCLC with activating EGFR mutations

2019 Scottish Medicines Consortium

16. Pembrolizumab (Keytruda) - non-small cell lung cancer (NSCLC) in adults.

Pembrolizumab (Keytruda) - non-small cell lung cancer (NSCLC) in adults. 1 Published 9 September 2019 1 SMC2187 pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) Merck Sharp & Dohme UK Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised (...) as follows: ADVICE: following a full submission assessed under the end of life medicine process pembrolizumab (Keytruda ® ) is accepted for restricted use within NHSScotland. Indication under review: In combination with carboplatin and either paclitaxel or nab- paclitaxel, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults. SMC restriction: in combination with carboplatin and paclitaxel in patients whose tumours express programmed death ligand 1 (PD-L1

2019 Scottish Medicines Consortium

17. Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment

Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment Daily online image-guided radiotherapy (lung cancer) - Health Technology Wales > Daily online image-guided radiotherapy (lung cancer) Daily online image-guided radiotherapy (lung cancer) Topic Status Complete Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health (...) Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER036 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full

2019 Health Technology Wales

18. Volumetric modulated arc radiotherapy for people with lung cancer

Volumetric modulated arc radiotherapy for people with lung cancer Volumetric modulated arc radiotherapy (lung cancer) - Health Technology Wales > Volumetric modulated arc radiotherapy (lung cancer) Volumetric modulated arc radiotherapy (lung cancer) Topic Status Complete Volumetric modulated arc radiotherapy for people with lung cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre (...) . It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER034 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking

2019 Health Technology Wales

19. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer P Pembrolizumab with carboplatin and embrolizumab with carboplatin and paclitax paclitaxel for untreated metastatic el for untreated metastatic squamous non-small-cell lung cancer squamous non-small-cell lung cancer T echnology appraisal guidance Published: 11 September 2019 www.nice.org.uk/guidance/ta600 © NICE 2019. All rights reserved. Subject to Notice of rights (https (...) to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600) © NICE 2019. All rights

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

20. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. (PubMed)

Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. Non-small cell lung cancer remains the leading cause of cancer death in the United States. Until the last decade, the 5-year overall survival rate for patients with metastatic non-small cell lung cancer was less than 5%. Improved understanding of the biology of lung cancer has resulted in the development of new biomarker-targeted therapies and led to improvements in overall survival for patients (...) with advanced or metastatic disease.Systemic therapy for metastatic non-small cell lung cancer is selected according to the presence of specific biomarkers. Therefore, all patients with metastatic non-small cell lung cancer should undergo molecular testing for relevant mutations and expression of the protein PD-L1 (programmed death ligand 1). Molecular alterations that predict response to treatment (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations) are present

2019 JAMA